CN86108119A - The strains A that the gentamicin component ratio is suitable 2And seed selection - Google Patents
The strains A that the gentamicin component ratio is suitable 2And seed selection Download PDFInfo
- Publication number
- CN86108119A CN86108119A CN86108119.6A CN86108119A CN86108119A CN 86108119 A CN86108119 A CN 86108119A CN 86108119 A CN86108119 A CN 86108119A CN 86108119 A CN86108119 A CN 86108119A
- Authority
- CN
- China
- Prior art keywords
- met
- methionine
- gentamicin
- saltant
- purple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to screening of microbial strains.The objective of the invention is with the short-cut method of the anti-methionine(Met) analog saltant of screening, to obtain the suitable production bacterial strain of gentamicin component ratio from changing strain properties.We produce bacterium with mutagenic compound mutagenesis gentamicin, screen on the substratum that contains methionine(Met) analog (as ethionine etc.), obtain three strain purple-red single-spore bacteria saltant A
2(Micromonospora purpurea A
2).With the fermented liquid ply of paper analyse, the way of biological developing measures gentamicinC
1, C
1a, C
2Ratio, the gained result reasonably well meets the pharmacopeia requirement.
Description
The invention belongs to screening of microbial strains.
Homemade gentamicin and external gentamycin (being gentamicin) all are the aminoglycosides antibiotics by the many components of gang of micromonospora generation.Its main component of the goods of Shi Yonging is C clinically
1, C
1a, C
2Because each component chemical structure difference, the toxicity that is showed are also different, the relative content of therefore controlling component in the gentamicin product is related to the result of treatment of medicine.
United States Patent (USP) (U.S.Patent 3,651,042(1972)) is introduced the main component of gentamycin: C
1Content is about 25%-50%, is generally 40%; C
1aContent is about 15%-40%, is generally 25%; C
2Content is about 20%-50%, is generally 35%.Isolated in China in 1967 goes out gentamicin and produces the bacterium purple-red single-spore bacteria, since the operation in 1969, and gentamicinC that each relevant pharmaceutical factory of China produces
2Compare C
1The content height, so the toxicity of medicine is bigger.Kaifeng pharmaceutical factory willow generation scholar (＜microbiotic〉8(1) 28-32(1983)) according to C
1, C
1a, C
2Chemical structure in C
1Contain methyl number this fact at most, in shake flask fermentation, add the DL-methionine(Met), improved gentamicinC
1Content.But owing to methionine(Met) costs an arm and a leg, can't be in industrial popularization.
The objective of the invention is to screen the saltant of anti-methionine(Met) analog,, obtain the suitable bacterial strain of gentamicin component ratio with this easy screening method from changing strain properties.
The present invention produces bacterial strain with nitrosoguanidine (other any mutagenic compound can) mutagenesis gentamicin, again the bacterial strain of the anti-methionine(Met) analog of screening on the substratum that contains methionine(Met) analog (as ethionine etc.).The methionine(Met) analog is produced bacterial strain to gentamicin and is had the effect that suppresses growth, regulate theoretical according to metabolism, can expect that the saltant of anti-methionine(Met) analog can make synthetic more methionine(Met) in the bacterial strain, become the source that more methyl are provided, thereby under the condition that does not change the substratum composition, make to contain the many gentamicinCs of methyl
1Content increases.
We produce bacterial strain #72 with the nitrosoguanidine mutagenesis gentamicin, on minimum medium, grow up to spore through the #72 of mutagenesis bacterial strain, sampling is placed on the substratum that contains methionine(Met) analog (as ethionine etc.) and grows then, after the resistance bacterium colony that grows is purified, connects the long spore in inclined-plane.Above-mentioned culture temperature and incubation time needn't be very strict, can as long as can form the culture condition of bacterium colony; The concentration of methionine(Met) analog is more than 50 mcg/ml in the substratum, generally in 50 mcg/ml to 5000 mcg/ml.
We screen the saltant A of the anti-ethionine of three strains with aforesaid method
2(Micromonspora purpurea A
2).Visual inspection: no aerial mycelium, the bacterium colony projection, it is luxuriant to grow, surperficial dark red brown, reverse side russet; Microscopic examination: mycelium is long, and branch does not have and separates, and diameter is about 0.5 micron.
Purple-red single-spore bacteria saltant A
2China Committee for Culture Collection of Microorganisms common micro-organisms center, preserving number CGMCC0118 have been deposited in on November 22nd, 1986.
We analyse with the fermented liquid ply of paper, and the way of biological developing is measured gentamicinC
1, C
1a, C
2Ratio, the gained result reasonably well meets the pharmacopeia requirement.Data see Table 1.
A
2Bacterial strain shows through producing last four tons of fermentation test results: A
2The total unit of strain fermentation is not less than and produces bacterial strain #72, uses A
2The gentamicin that bacterial strain is produced is better than the gentamicin quality of producing bacterial strain production with #72.
Gentamicin is the active drug that control streptococcus aureus, Pseudomonas aeruginosa, intestinal bacteria and Bacillus proteus etc. infect, and also is one of microbiotic of China's outlet.The bacterial strain that the present invention uses the short-cut method of anti-methionine(Met) analog (as ethionine etc.) to screen can be produced the suitable gentamicin of component ratio, has reduced the toxicity of medicine, is of value to people's health; And can improve homemade gentamicin competitive capacity in the international market, increase national foreign exchange income.
Be embodiments of the invention below:
The strain inclined plane Micromonospora purpurea#72 that uses in the fresh production digs piece and is inoculated in the triangular flask that contains nutrient solution, with 230 rev/mins, 33 ℃ shaking culture 48 hours, and centrifugal collection mycelia; With the phosphoric acid buffer washed twice of 0.03M, mycelia
Again be suspended from the phosphoric acid solution; Break up mycelia with granulated glass sphere, filter, obtain mycelia small segment suspension with the dual-layer sterilization toilet paper.Take by weighing 1mg NTG, be dissolved in the 0.1ml methane amide, add mycelia fragment suspension 4.9ml, put 37 ℃ and handled 90 minutes, with 3000 rev/mins centrifugal 10 minutes, supernatant liquor inclines; The mycelia fragment that mutagenic treatment is crossed is suspended from the phosphoric acid buffer, and sampling is coated on the minimum medium, cultivates 7 days for 37 ℃; Wash spore with sterile purified water, break up with granulated glass sphere, with the mycelia of the netted growth of dual-layer sterilization toilet paper elimination, the preparation monospore suspension.Sampling is coated on the minimum medium that contains ethionine 3000 mcg/ml, cultivates 15 days for 37 ℃, connects the inclined-plane after the resistance bacterium colony of appearance is purified, and behind the long good spore, it is standby to put 4 ℃ of refrigerators.
Micromonospora purpurea A with fresh anti-ethionine
2The inclined-plane digs piece and is inoculated into 250ml and contains shaking in the bottle of seed culture medium 30ml, 33 ℃, 230 rev/mins shaking culture 2 days; Be transferred on the fermention medium shaking culture 5 days by 10% inoculum size; Fermented liquid is with the portable measuring method for measuring of Shanghai the 4th pharmaceutical factory's gentamicin component (＜medicine industry〉(9) 8-14(1979)) carry out the quantitative assay each component.
Claims (3)
1, a kind of microorganism strains, the purple-red single-spore bacteria saltant, visual inspection is no aerial mycelium, microscopic examination mycelium length, branch, nothing are separated, and it is characterized in that A
2Bacterial strain (Micromonospora purpurea A
2) have a characteristic of anti-ethionine or anti-other methionine(Met) analogs.
2, a kind of selection of microorganism strains, the selection of purple-red single-spore bacteria saltant, comprise with mutagenic compound mutagenesis purple-red single-spore bacteria, it is characterized in that, be placed on the substratum that contains ethionine or other methionine(Met) analogs through the purple-red single-spore bacteria of mutagenesis and cultivate, connect the long spore in inclined-plane after the resistance bacterium colony that grows is purified.
3, by the described method for strain breeding thereof of claim 2, wherein, the concentration of above-mentioned ethionine or other methionine(Met) analogs is that 50 mcg/ml are to 5000 mcg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 86108119 CN1008445B (en) | 1986-12-03 | 1986-12-03 | Strain a2 with proper component ratio gentamycin and its selective culture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 86108119 CN1008445B (en) | 1986-12-03 | 1986-12-03 | Strain a2 with proper component ratio gentamycin and its selective culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN86108119A true CN86108119A (en) | 1988-06-15 |
| CN1008445B CN1008445B (en) | 1990-06-20 |
Family
ID=4803807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 86108119 Expired CN1008445B (en) | 1986-12-03 | 1986-12-03 | Strain a2 with proper component ratio gentamycin and its selective culture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1008445B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025566A1 (en) * | 1993-04-23 | 1994-11-10 | Jiangsu Institute Of Microbiology | 1-n-ethyl gentamicin derivatives, and the method for preparing thereof |
| CN1063483C (en) * | 1995-08-23 | 2001-03-21 | 中国科学院上海植物生理研究所 | High-butanol ratio clostridium acetobutylicium and culturing method and use thereof |
| CN102586146A (en) * | 2011-12-19 | 2012-07-18 | 沈阳药科大学 | Engineering bacteria for generating gentamicin C1a and constructing method of engineering bacteria |
| CN103160552A (en) * | 2013-02-24 | 2013-06-19 | 烟台只楚药业有限公司 | Preparation method of gentamicin sulphate |
| CN103740627A (en) * | 2013-11-30 | 2014-04-23 | 福州市鼓楼区荣德生物科技有限公司 | Gentamycin JI-20B gene engineering bacterium, and construction and application thereof |
| CN113403237A (en) * | 2021-07-27 | 2021-09-17 | 青岛安惠仕生物制药有限公司 | Gentamicin sulfate prepared by enhanced microbial fermentation and application method thereof |
-
1986
- 1986-12-03 CN CN 86108119 patent/CN1008445B/en not_active Expired
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025566A1 (en) * | 1993-04-23 | 1994-11-10 | Jiangsu Institute Of Microbiology | 1-n-ethyl gentamicin derivatives, and the method for preparing thereof |
| US5814488A (en) * | 1993-04-23 | 1998-09-29 | Jiansgu Institute Of Microbiology | Semisynthetic 1-N-ethylgentamicin C1a and method for its preparation |
| CN1040177C (en) * | 1993-04-23 | 1998-10-14 | 江苏省微生物研究所 | 1-N-ethyl gentamicin derivative and its preparing method |
| CN1063483C (en) * | 1995-08-23 | 2001-03-21 | 中国科学院上海植物生理研究所 | High-butanol ratio clostridium acetobutylicium and culturing method and use thereof |
| CN102586146A (en) * | 2011-12-19 | 2012-07-18 | 沈阳药科大学 | Engineering bacteria for generating gentamicin C1a and constructing method of engineering bacteria |
| CN102586146B (en) * | 2011-12-19 | 2014-04-23 | 沈阳药科大学 | Engineering bacteria for generating gentamicin C1a and constructing method of engineering bacteria |
| CN103160552A (en) * | 2013-02-24 | 2013-06-19 | 烟台只楚药业有限公司 | Preparation method of gentamicin sulphate |
| CN103160552B (en) * | 2013-02-24 | 2015-01-21 | 烟台只楚药业有限公司 | Preparation method of gentamicin sulphate |
| CN103740627A (en) * | 2013-11-30 | 2014-04-23 | 福州市鼓楼区荣德生物科技有限公司 | Gentamycin JI-20B gene engineering bacterium, and construction and application thereof |
| CN113403237A (en) * | 2021-07-27 | 2021-09-17 | 青岛安惠仕生物制药有限公司 | Gentamicin sulfate prepared by enhanced microbial fermentation and application method thereof |
| CN113403237B (en) * | 2021-07-27 | 2021-12-28 | 青岛安惠仕生物制药有限公司 | Gentamicin sulfate prepared by enhanced microbial fermentation and application method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1008445B (en) | 1990-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114875016B (en) | Formulated carrier suitable for pseudomonas fluorescens and microbial inoculum thereof | |
| CN108624524A (en) | The bacterial strain and its separating screening method of one plant of production bacteria cellulose | |
| CN86108119A (en) | The strains A that the gentamicin component ratio is suitable 2And seed selection | |
| Leggatt et al. | Characterisation of micro-organisms isolated from plants during micropropagation | |
| KR19990079232A (en) | Lactobacillus plantarum pmeo 08 (KF-11028) microbe having cholesterol lowering ability | |
| US11805783B2 (en) | Growth-promoting bacterial agent capable of improving content of soybean oil, preparation method and use thereof | |
| CN111411056A (en) | Lactobacillus paracasei subspecies tenacious strain, screening method and application | |
| US6010898A (en) | Liquid cultivation of strains of Bacillus polyfermenticus | |
| CN110331104A (en) | A kind of lactobacillus plantarum CV10D1 and its application | |
| CN114231460B (en) | Bacillus subtilis, composition and application thereof, and fermentation culture method of bacillus subtilis | |
| James | YELLOW CHROMOGENIC BACTERIA ON WHEAT: II. DETERMINATIVE STUDIES | |
| KR20020067226A (en) | Producing method of microbial cellulose by mixed culture | |
| CN110012941B (en) | Method for preparing fermented soybean milk by using paenibacillus, fermented soybean milk prepared by method and application of fermented soybean milk | |
| US5171836A (en) | Antibiotics plusbacin | |
| CN117431194B (en) | Bacillus amyloliquefaciens, composition and application thereof in cut-flower Paeonia lactiflora | |
| KR100280189B1 (en) | Microorganisms That Produce Cephalosporin C and Methods of Making Cephalosporin C Using the Same | |
| CN115895972B (en) | Composite microbial inoculum and application thereof in prevention and control of tobacco soil-borne diseases | |
| CN112715577B (en) | Application of matrine and beauveria bassiana in preventing and treating common circium japonicum | |
| KR920000115B1 (en) | New microorganism streptococcus sp | |
| Arkwright | Natural variation of B. acidi lactici with respect to the production of gas from carbohydrates | |
| CN113773979A (en) | Preparation and application of active bacterium Bacillus sp for inhibiting tobacco mildew | |
| SU1503295A1 (en) | Fungus strain fusarium sporotrichiella used for obtaining t-2 toxin | |
| CA1046438A (en) | Production of kitasamycin (leucomycin) complex from streptomyces kitasatoensis | |
| SU1631083A1 (en) | Strain of actinomycet streptomyces lavendulae subsparuptini for producing aruptin | |
| CN116445324A (en) | Staphylococci screening and enzyme activity condition optimization of non-pathogenic protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C13 | Decision | ||
| C14 | Grant of patent or utility model | ||
| C19 | Lapse of patent right due to non-payment of the annual fee |